Six-Transmembrane Epithelial Antigen of the Prostate as an Immunotherapeutic Target for Renal Cell and Bladder Cancer

Journal of Urology

Volumn 183, Issue 5, 2010, Pages 2036-2044

  Azumi, Makoto ^a   Kobayashi, Hiroya ^a   Aoki, Naoko ^a   Sato, Keisuke ^a   Kimura, Shoji ^a   Kakizaki, Hidehiro ^a   Tateno, Masatoshi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

carcinoma, renal cell; immunology; STEAP1 protein, human; T lymphocytes, helper inducer; urinary bladder neoplasms

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROSTATE ANTIGEN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HLA-DR ANTIGENS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; KIDNEY NEOPLASMS; OXIDOREDUCTASES; T-LYMPHOCYTES, HELPER-INDUCER; TRANSFECTION; URINARY BLADDER NEOPLASMS;

EID: 77950464523     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.12.094     Document Type: Article

References (16)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71
2. Rosenberg S.A., Yang J.C., White D.E., et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg 228 (1998) 307
3. Gouttefangeas C., Stenzl A., Stevanovic S., et al. Immunotherapy of renal cell carcinoma. Cancer Immunol Immunother 56 (2007) 117
4. Hubert R.S., Vivanco I., Chen E., et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 96 (1999) 14523
5. Rodeberg D.A., Nuss R.A., Elsawa S.F., et al. Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes. Clin Cancer Res 11 (2005) 4545
6. Machlenkin A., Paz A., Bar Haim E., et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 65 (2005) 6435
7. Kobayashi H., Nagato T., Sato K., et al. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res 67 (2007) 5498
8. Challita-Eid P.M., Morrison K., Etessami S., et al. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 67 (2007) 5798
9. Kobayashi H., Wood M., Song Y., et al. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res 60 (2000) 5228
10. Kobayashi H., Nagato T., Takahara M., et al. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res 68 (2008) 901
11. Janssen E.M., Droin N.M., Lemmens E.E., et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434 (2005) 88
12. Hahn S., Gehri R., and Erb P. Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol Rev 146 (1995) 57
13. Haigh T.A., Lin X., Jia H., et al. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4+ cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol 180 (2008) 1643
14. Ohgami R.S., Campagna D.R., McDonald A., et al. The Steap proteins are metalloreductases. Blood 108 (2006) 1388
15. Yang D., Holt G.E., Velders M.P., et al. Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Res 61 (2001) 5857
16. Southwood S., Sidney J., Kondo A., et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 160 (1998) 3363